Ipsen Sa Company Profile and Market Insights

Ipsen is a global biopharmaceutical company that has been in operation since 1929. It's a French company with its headquarters in Boulogne-Billancourt.

Ipsen has a diverse portfolio of innovative treatments in oncology and rare diseases. The company has a strong presence in over 115 countries.

Ipsen's focus on oncology is evident in its research and development efforts, with a pipeline of treatments in various stages of development.

Ipsen's financial performance has been impressive, with total revenue reaching EUR 915 million in the third quarter, a nearly 14% year-over-year increase.

The company's management has upgraded its 2025 outlook, expecting total sales growth of around 10% and a core operating margin of 35%. This is a significant improvement from previous estimates.

Ipsen's profitability metrics are also noteworthy, with a return on assets (normalized) of 14.55%, return on equity (normalized) of 22.96%, and return on invested capital (normalized) of 20.66%.

Ipsen's recent earnings report is a great example of a company that's on the right track. Their total revenue in the third quarter was EUR 915 million, a nearly 14% increase year over year.

This growth is a testament to Ipsen's strong performance. Management has even upgraded their 2025 outlook to total sales growth of around 10% and core operating margin of 35%. That's a significant increase in their expectations.

Ipsen's financial health is also looking good. Their quick ratio is 1.70, which indicates they have a solid ability to pay off their short-term debts. In comparison, UCB has a quick ratio of 1.00.

Here's a comparison of Ipsen's financial metrics with UCB and JAZZ:

It's worth noting that Ipsen's return on assets (normalized) is 14.55%, which is significantly higher than UCB's 7.31% and JAZZ's 3.64%. This indicates that Ipsen is making the most of their assets.

Ipsen's financial performance is heavily influenced by the price vs value dynamic in the pharmaceutical industry. Many of Ipsen's products are facing competitive pressures from lower-priced generics.

This shift in the market has significant implications for Ipsen's revenue streams. The company's ability to maintain its market share and pricing power is crucial to its financial performance.

Ipsen's products are often priced higher than their generic counterparts, but the company must balance this with the need to remain competitive. This delicate balance can be challenging to achieve in a market where consumers are increasingly price-sensitive.

As a result, Ipsen must carefully manage its pricing strategy to ensure that its products remain attractive to customers while also maintaining profitability. This requires a deep understanding of the market and the needs of Ipsen's customers.

Ipsen SA's commercialized product portfolio is a key factor in its financial performance.

One of the notable products is a marketed drug. Ipsen SA has a significant presence in the market with its commercialized products.

Ipsen SA's marketed drugs have contributed to its revenue growth.

A unique perspective: Worldline SA

Ipsen is a global biopharmaceutical company with a strong presence in the market. It has a diverse portfolio of products across various therapeutic areas.

Ipsen's growth strategy is focused on innovation and expansion. The company has a robust pipeline of products in development, including oncology and rare disease treatments.

Ipsen has a significant presence in the US market, with a range of products approved and marketed in the country. Its US sales have been growing steadily over the years.

The company's focus on innovation has led to the development of several first-in-class products. These products have been well-received by the market and have contributed to Ipsen's growth.

Ipsen's partnerships with other companies have also played a crucial role in its growth strategy. The company has partnered with several leading pharmaceutical companies to develop and market new products.

Ipsen's commitment to research and development has led to the creation of a robust pipeline of products. This pipeline includes several promising candidates in the oncology and rare disease areas.

Ipsen's financial performance has been strong, with the company reporting significant revenue growth in recent years. Its financial stability has enabled it to invest in new products and expand its operations.

Additional reading: Concord New Energy

Ipsen is a biopharmaceutical company based in France, offering a diverse range of products across various therapeutic areas, including oncology, neuroscience, consumer healthcare, and rare disease.

The company has a strong global presence, with its products available in over 115 countries. Ipsen has R&D and manufacturing facilities in several countries, including China, France, Ireland, the United Kingdom, and the United States.

Ipsen's product portfolio includes notable treatments such as Onivyde, which is used to treat patients with metastatic adenocarcinoma of the pancreas, and Dysport, a neurotoxin used for various medical and cosmetic purposes.

A fresh viewpoint: United Aircraft and Transport Corporation

Ipsen SA is a company based in France, with a history dating back to 1929. They offer a diverse range of products across various therapeutic areas.

Their products include carbometyx, cometriq, decapeptyl, dysport, increlex, nutropinAq, onivyde, somatuline, and xermelo, which cater to oncology, neuroscience, consumer healthcare, and rare disease markets.

The company has a significant presence worldwide, with operations in over 30 countries and a pipeline of products in various stages of development. They have invested $476.22 million in R&D, which is 14.9% of their sales.

Here are some key statistics about Ipsen SA:

Ipsen SA has a strong research and development focus, with a significant investment in oncology, rare disease, and neuroscience areas.

Ipsen SA's digital strategy is informed by its likely spend across technology areas, as reported by IT Client Prospector.

This likely spend enables Ipsen SA to understand its ICT (Information and Communication Technology) priorities, which are crucial for its business operations.

Ipsen SA's ICT spend and priorities are essential for its digital transformation, which is a key aspect of its overall business strategy.

IT Client Prospector provides valuable insights into Ipsen SA's ICT spend, helping businesses understand its digital strategy and make informed decisions.

For more insights, see: Business & Decision

Ipsen is a global specialty pharmaceutical company with a rich history dating back to 1929. The company was founded by Charles Ipsen in Denmark and has since grown to become a leading player in the industry.

Ipsen has a strong presence in the neurology and urology markets, with a portfolio of innovative treatments for conditions such as multiple sclerosis, Parkinson's disease, and benign prostatic hyperplasia.

The company's commitment to research and development is evident in its robust pipeline of new products, which includes several promising candidates in Phase III clinical trials.

Ipsen has been actively involved in research and development, particularly in the area of cancer treatment. In 2021, they introduced Phase 1/2 clinical data of Liposomal Irinotecan or Onivyde at the ESMO world congress on Gastrointestinal cancer.

The data showcased the potential of Onivyde as a first-line treatment for metastatic pancreatic cancer. Ipsen Pharma has been working tirelessly to advance this treatment option.

In 2020, Ipsen received FDA Fast Track designation for Onivyde as a second-line monotherapy treatment for small cell lung cancer.

Here's a summary of the key developments:

Ipsen's history is a fascinating story of growth and expansion. In 2025, the company made significant strides, signing an agreement to acquire ImCheck Therapeutics, a biotechnology company.

This acquisition marked a major milestone for Ipsen, expanding its capabilities and offerings. Ipsen also received a marketing authorization from the U.K. Medicines and Healthcare products Regulatory Agency for cabozantinib in adult patients with unresectable or metastatic, well-differentiated pNETs and epNETs in 2025.

Regulatory approvals like this one demonstrate Ipsen's commitment to bringing innovative treatments to market. In July 2025, Ipsen opened its new headquarters in Paris, France, marking another significant corporate change and expansion.

Here are the key events from Ipsen's history in 2025:

Ipsen has been making significant strides in the field of cancer treatment. In July 2021, the company introduced Phase 1/2 clinical data of Liposomal Irinotecan, also known as Onivyde liposomal, as an investigational first-line drug for metastatic pancreatic cancer at the ESMO world congress on Gastrointestinal cancer.

This development is a promising step towards finding new treatments for pancreatic cancer. Ipsen Pharma launched the clinical data at a major conference, showcasing the potential of Onivyde liposomal in this area.

In November 2020, Ipsen Pharma received FDA Fast Track designation for investigational liposome injection, Onivyde. This designation allows the company to expedite the development and review of Onivyde as a second-line monotherapy treatment for small cell lung cancer.

Ipsen's focus on cancer treatment has led to significant advancements in recent years. The company's commitment to finding new treatments has made a real difference in the lives of patients.

Here are some key dates related to Ipsen's recent developments:

Ipsen has a strong commitment to protecting its intellectual property, with a portfolio of over 150 patents worldwide. This focus on innovation has allowed the company to stay ahead in the industry.

The company's research and development efforts have led to the creation of several innovative products, including Onivyde, a treatment for pancreatic cancer that was granted FDA approval in 2015.

Ipsen's dedication to research and development has resulted in a significant number of patent applications, with the company investing heavily in its R&D efforts.

The company's success has been recognized with several awards, including the 2019 Prix Galien, which honors innovative pharmaceutical products that have made a significant impact on human health.

Ipsen is facing several key challenges that could impact its future growth and success. One of the main concerns is the pressure from generic versions of Somatuline, which could weigh on future revenue despite current stable sales.

The company is also at risk due to its clinical trials, particularly FALKON and LANT, whose results will determine the future growth momentum.

Ipsen needs to maintain its dynamic research and development (R&D) efforts to support its growth in a highly competitive pharmaceutical landscape.

The sentiment of analysts can be volatile, and if their expectations are not fully met, it could affect the stock price.

Here are the main societal challenges Ipsen is facing: